These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 6206841)

  • 1. The NCI preclinical screen of biological response modifiers.
    Talmadge JE; Fidler IJ; Oldham RK
    Behring Inst Mitt; 1984 May; (74):189-94. PubMed ID: 6206841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical considerations for the establishment of a screening procedure for the assessment of biological response modifiers.
    Talmadge JE; Oldham RK; Fidler IJ
    J Biol Response Mod; 1984; 3(1):88-109. PubMed ID: 6707701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor models to investigate the therapeutic efficiency of immunomodulators.
    Talmadge E; Lenz BF; Collins MS; Uithoven KA; Schneider MA; Adams JS; Pearson JW; Agee WJ; Fox RE; Oldham RK
    Behring Inst Mitt; 1984 May; (74):219-29. PubMed ID: 6477354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological Response Modifiers Programme and cancer chemotherapy.
    Oldham RK
    Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of clinical trials with biological response modifiers.
    Herberman RB
    Cancer Treat Rep; 1985 Oct; 69(10):1161-4. PubMed ID: 2412692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological response modifiers for the therapy of cancer.
    Herberman RB
    Ann Allergy; 1985 May; 54(5):376-80. PubMed ID: 3994067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical approaches to the development of effective immunotherapeutic protocols for the treatment of metastasis.
    Talmadge JE
    Prog Clin Biol Res; 1986; 212():197-215. PubMed ID: 3520577
    [No Abstract]   [Full Text] [Related]  

  • 8. Cancer therapy by biological response modifiers.
    Herberman RB
    Clin Physiol Biochem; 1987; 5(3-4):238-48. PubMed ID: 2441918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future directions in the therapy for large bowel cancer.
    Carter SK
    Cancer; 1982 Dec; 50(11 Suppl):2647-56. PubMed ID: 6182979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological response modifiers.
    Oldham RK
    J Natl Cancer Inst; 1983 May; 70(5):789-96. PubMed ID: 6188871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo and in vivo characterization of biological response modifiers (BRMs).
    Masihi KN; Talmadge JE
    Dev Biol Stand; 1992; 77():143-5. PubMed ID: 1426655
    [No Abstract]   [Full Text] [Related]  

  • 12. A sequential multi-assay protocol for the preclinical assessment of natural product complex carbohydrate immunomodulators.
    Williams DL; Pretus HA; McNamee RB; Jones EL
    Dev Biol Stand; 1992; 77():129-36. PubMed ID: 1426653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers.
    Talmadge JE; Herberman RB
    Cancer Treat Rep; 1986 Jan; 70(1):171-82. PubMed ID: 3510733
    [No Abstract]   [Full Text] [Related]  

  • 14. Biologicals and biological response modifiers: fourth modality of cancer treatment.
    Oldham RK
    Cancer Treat Rep; 1984 Jan; 68(1):221-32. PubMed ID: 6198081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
    Weiner GJ
    J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer vaccines: preclinical studies and novel strategies.
    Palena C; Abrams SI; Schlom J; Hodge JW
    Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bio-immunotherapy for cancer in experimental studies and clinical application: current status and future challenges.
    Shen RN; Lu L; Kaiser HE; Broxmeyer HE
    In Vivo; 1994; 8(5):643-52. PubMed ID: 7727711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.